trial

Cognitive Impairments in Psychotic Disorders

NCTId NCT05597579
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 200 (estimated)
Sponsored by Sheba Medical Center
Primary completion 2023-05-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
200 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2020-02-12
Primary completion
2023-05-01
Eligibility
ALL · 18 Years · 30 Years

Interventions & indications

Drugs
DAPAR Tests (IQ equivalent test)

Sponsors

Sheba Medical CenterLead Sponsor

Investigators

1
Mark Weiser, MDPrincipal Investigator

Sites

1 total
Ramat Gan, Israel

Facts & assertions

4 sourced
Enrollment
200
Phase
NA
Primary Completion Date
2023-05-01
Status
UNKNOWN
relationships
The graph out of here
drug
DAPAR Tests (IQ equivalent test)
drug
lead_sponsor
Sheba Medical Center
company
indication
Psychotic Disorders
indication
Cognitive Dysfunction
indication
Psychotic Disorders
indication
investigator
Mark Weiser, MD
person